T1 news halt
$Cerus(CERS.US$ Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
